As Covid-19 spreads, disruptions to clinical trial and drug development accelerate
The disruption of clinical trials due to the novel coronavirus pandemic is becoming an almost daily ritual.
The scope of the clinical trial delays and suspension — like just about everything touched by this expanding crisis — is hard to quantify, but consider this snapshot: Biotech and pharma companies are currently running more than 120 Phase 3 clinical trials with top-line data readouts expected before the end of the year, according to search of a database maintained by BioMedTracker.
